Adenosine receptor activation ameliorates type 1 diabetes

D. Bleich, B. Csóka, Z.H. Nemeth, P. Pacher, Jon Mabley, L. Himer, E.S. Vizi, E.A. Deitch, C. Szabo, B.N. Cronstein, G. Hasko

Research output: Contribution to journalArticle

Abstract

Growing evidence indicates that adenosine receptors could be promising therapeutic targets in autoimmune diseases. Here we studied the role of adenosine receptors in controlling the course of type 1 diabetes. Diabetes in CD-1 mice was induced by multiple-low-dose-streptozotocin (MLDS) treatment and in nonobese diabetic (NOD) mice by cyclophosphamide injection. The nonselective adenosine receptor agonist 5'-N-ethylcarboxamidoadenosine (NECA) prevented diabetes development in both MLDS-challenged mice and in cyclophosphamide-treated NOD mice. The effect of NECA was reversed by the selective A2B receptor antagonist N-(4-cyanophenyl)-2-[4-(2,3,6,7-tetrahydro-2,6-dioxo-1,3-dipropyl-1H-purin-8-yl)phenoxy]acetamide (MRS 1754). The selective A1 receptor agonist 2-chloro-N6-cyclopentyladenosine (CCPA) and A3 receptor agonist N6-(3-iodobenzyl)-adenosine-5'-N-methyluronamide (IB-MECA) were less efficacious in ameliorating the course of diabetes. NECA inhibited diabetes in A2A receptor KO mice and the selective A2A receptor agonist 2-p-(2-carboxyethyl)phenethyl-amino-5'-N-ethyl-carboxamidoadenosine (CGS21680) had no effect in normal mice, indicating a lack of role of A2A receptors. NECA failed to prevent cytokine-induced beta-cell death in vitro, but NECA strongly suppressed expression of the proinflammatory cytokines TNF-alpha, MIP-1alpha, IL-12, and IFN-gamma in pancreata, endotoxin, or anti-CD3-stimulated splenic cells, and T helper 1 lymphocytes, indicating that the beneficial effect of NECA was due to immunomodulation. These results demonstrate that adenosine receptor ligands are potential candidates for the treatment of type 1 diabetes.
Original languageEnglish
Pages (from-to)2379-2388
Number of pages10
JournalFaseb journal
Volume21
Issue number10
Publication statusPublished - 31 Aug 2007

Fingerprint

Adenosine-5'-(N-ethylcarboxamide)
Purinergic P1 Receptors
Type 1 Diabetes Mellitus
Inbred NOD Mouse
Streptozocin
Cyclophosphamide
Purinergic P1 Receptor Agonists
Cytokines
Chemokine CCL3
Immunomodulation
Interleukin-12
Helper-Inducer T-Lymphocytes
Endotoxins
Adenosine
Autoimmune Diseases
Pancreas
Cell Death
Therapeutics
Tumor Necrosis Factor-alpha
Ligands

Cite this

Bleich, D., Csóka, B., Nemeth, Z. H., Pacher, P., Mabley, J., Himer, L., ... Hasko, G. (2007). Adenosine receptor activation ameliorates type 1 diabetes. Faseb journal, 21(10), 2379-2388.
Bleich, D. ; Csóka, B. ; Nemeth, Z.H. ; Pacher, P. ; Mabley, Jon ; Himer, L. ; Vizi, E.S. ; Deitch, E.A. ; Szabo, C. ; Cronstein, B.N. ; Hasko, G. / Adenosine receptor activation ameliorates type 1 diabetes. In: Faseb journal. 2007 ; Vol. 21, No. 10. pp. 2379-2388.
@article{099079582e244193a76aae7702c2e251,
title = "Adenosine receptor activation ameliorates type 1 diabetes",
abstract = "Growing evidence indicates that adenosine receptors could be promising therapeutic targets in autoimmune diseases. Here we studied the role of adenosine receptors in controlling the course of type 1 diabetes. Diabetes in CD-1 mice was induced by multiple-low-dose-streptozotocin (MLDS) treatment and in nonobese diabetic (NOD) mice by cyclophosphamide injection. The nonselective adenosine receptor agonist 5'-N-ethylcarboxamidoadenosine (NECA) prevented diabetes development in both MLDS-challenged mice and in cyclophosphamide-treated NOD mice. The effect of NECA was reversed by the selective A2B receptor antagonist N-(4-cyanophenyl)-2-[4-(2,3,6,7-tetrahydro-2,6-dioxo-1,3-dipropyl-1H-purin-8-yl)phenoxy]acetamide (MRS 1754). The selective A1 receptor agonist 2-chloro-N6-cyclopentyladenosine (CCPA) and A3 receptor agonist N6-(3-iodobenzyl)-adenosine-5'-N-methyluronamide (IB-MECA) were less efficacious in ameliorating the course of diabetes. NECA inhibited diabetes in A2A receptor KO mice and the selective A2A receptor agonist 2-p-(2-carboxyethyl)phenethyl-amino-5'-N-ethyl-carboxamidoadenosine (CGS21680) had no effect in normal mice, indicating a lack of role of A2A receptors. NECA failed to prevent cytokine-induced beta-cell death in vitro, but NECA strongly suppressed expression of the proinflammatory cytokines TNF-alpha, MIP-1alpha, IL-12, and IFN-gamma in pancreata, endotoxin, or anti-CD3-stimulated splenic cells, and T helper 1 lymphocytes, indicating that the beneficial effect of NECA was due to immunomodulation. These results demonstrate that adenosine receptor ligands are potential candidates for the treatment of type 1 diabetes.",
author = "D. Bleich and B. Cs{\'o}ka and Z.H. Nemeth and P. Pacher and Jon Mabley and L. Himer and E.S. Vizi and E.A. Deitch and C. Szabo and B.N. Cronstein and G. Hasko",
year = "2007",
month = "8",
day = "31",
language = "English",
volume = "21",
pages = "2379--2388",
journal = "The FASEB Journal",
issn = "0892-6638",
number = "10",

}

Bleich, D, Csóka, B, Nemeth, ZH, Pacher, P, Mabley, J, Himer, L, Vizi, ES, Deitch, EA, Szabo, C, Cronstein, BN & Hasko, G 2007, 'Adenosine receptor activation ameliorates type 1 diabetes', Faseb journal, vol. 21, no. 10, pp. 2379-2388.

Adenosine receptor activation ameliorates type 1 diabetes. / Bleich, D.; Csóka, B.; Nemeth, Z.H.; Pacher, P.; Mabley, Jon; Himer, L.; Vizi, E.S.; Deitch, E.A.; Szabo, C.; Cronstein, B.N.; Hasko, G.

In: Faseb journal, Vol. 21, No. 10, 31.08.2007, p. 2379-2388.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Adenosine receptor activation ameliorates type 1 diabetes

AU - Bleich, D.

AU - Csóka, B.

AU - Nemeth, Z.H.

AU - Pacher, P.

AU - Mabley, Jon

AU - Himer, L.

AU - Vizi, E.S.

AU - Deitch, E.A.

AU - Szabo, C.

AU - Cronstein, B.N.

AU - Hasko, G.

PY - 2007/8/31

Y1 - 2007/8/31

N2 - Growing evidence indicates that adenosine receptors could be promising therapeutic targets in autoimmune diseases. Here we studied the role of adenosine receptors in controlling the course of type 1 diabetes. Diabetes in CD-1 mice was induced by multiple-low-dose-streptozotocin (MLDS) treatment and in nonobese diabetic (NOD) mice by cyclophosphamide injection. The nonselective adenosine receptor agonist 5'-N-ethylcarboxamidoadenosine (NECA) prevented diabetes development in both MLDS-challenged mice and in cyclophosphamide-treated NOD mice. The effect of NECA was reversed by the selective A2B receptor antagonist N-(4-cyanophenyl)-2-[4-(2,3,6,7-tetrahydro-2,6-dioxo-1,3-dipropyl-1H-purin-8-yl)phenoxy]acetamide (MRS 1754). The selective A1 receptor agonist 2-chloro-N6-cyclopentyladenosine (CCPA) and A3 receptor agonist N6-(3-iodobenzyl)-adenosine-5'-N-methyluronamide (IB-MECA) were less efficacious in ameliorating the course of diabetes. NECA inhibited diabetes in A2A receptor KO mice and the selective A2A receptor agonist 2-p-(2-carboxyethyl)phenethyl-amino-5'-N-ethyl-carboxamidoadenosine (CGS21680) had no effect in normal mice, indicating a lack of role of A2A receptors. NECA failed to prevent cytokine-induced beta-cell death in vitro, but NECA strongly suppressed expression of the proinflammatory cytokines TNF-alpha, MIP-1alpha, IL-12, and IFN-gamma in pancreata, endotoxin, or anti-CD3-stimulated splenic cells, and T helper 1 lymphocytes, indicating that the beneficial effect of NECA was due to immunomodulation. These results demonstrate that adenosine receptor ligands are potential candidates for the treatment of type 1 diabetes.

AB - Growing evidence indicates that adenosine receptors could be promising therapeutic targets in autoimmune diseases. Here we studied the role of adenosine receptors in controlling the course of type 1 diabetes. Diabetes in CD-1 mice was induced by multiple-low-dose-streptozotocin (MLDS) treatment and in nonobese diabetic (NOD) mice by cyclophosphamide injection. The nonselective adenosine receptor agonist 5'-N-ethylcarboxamidoadenosine (NECA) prevented diabetes development in both MLDS-challenged mice and in cyclophosphamide-treated NOD mice. The effect of NECA was reversed by the selective A2B receptor antagonist N-(4-cyanophenyl)-2-[4-(2,3,6,7-tetrahydro-2,6-dioxo-1,3-dipropyl-1H-purin-8-yl)phenoxy]acetamide (MRS 1754). The selective A1 receptor agonist 2-chloro-N6-cyclopentyladenosine (CCPA) and A3 receptor agonist N6-(3-iodobenzyl)-adenosine-5'-N-methyluronamide (IB-MECA) were less efficacious in ameliorating the course of diabetes. NECA inhibited diabetes in A2A receptor KO mice and the selective A2A receptor agonist 2-p-(2-carboxyethyl)phenethyl-amino-5'-N-ethyl-carboxamidoadenosine (CGS21680) had no effect in normal mice, indicating a lack of role of A2A receptors. NECA failed to prevent cytokine-induced beta-cell death in vitro, but NECA strongly suppressed expression of the proinflammatory cytokines TNF-alpha, MIP-1alpha, IL-12, and IFN-gamma in pancreata, endotoxin, or anti-CD3-stimulated splenic cells, and T helper 1 lymphocytes, indicating that the beneficial effect of NECA was due to immunomodulation. These results demonstrate that adenosine receptor ligands are potential candidates for the treatment of type 1 diabetes.

M3 - Article

VL - 21

SP - 2379

EP - 2388

JO - The FASEB Journal

JF - The FASEB Journal

SN - 0892-6638

IS - 10

ER -

Bleich D, Csóka B, Nemeth ZH, Pacher P, Mabley J, Himer L et al. Adenosine receptor activation ameliorates type 1 diabetes. Faseb journal. 2007 Aug 31;21(10):2379-2388.